Side-by-side comparison

NVO vs BSX — Side-by-side comparison

BSX screens cheaper on EV/FCF, BSX has the higher ROIC, BSX has grown revenue faster over five years, and BSX has the cleaner balance sheet by net debt / EBITDA.

NVO

Novo Nordisk A S

Price

$44.96

Market cap

$305.8B

Day %

N/A

BSX

Boston Scientific

Price

$57.78

Market cap

$154.2B

Day %

N/A

Peer Comparison

Target stock against 1 market-cap comparable peer.

Heat map: red worst to green best


NVO Target	Novo Nordisk A S	$305.8B	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BSX	Boston Scientific	$154.2B	29.8x	41.6x	11.9%	15.2%	18.2%	69.0%	-0.4x	N/A

NVO implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

N/A

FCF yield

N/A

5Y rev CAGR

N/A

BSX implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

41.6x

FCF yield

2.4%

5Y rev CAGR

15.2%

5Y indexed stock chart

Static Recharts view indexed to 100 from available annual per-share data.

Quality Scorecard

Build-time composite score for NVO.

Grade F

/ 100

Quality Scorecard

Build-time composite score for BSX.

Grade C

/ 100